COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis.
Adult
Antiviral Agents
/ therapeutic use
Betacoronavirus
/ genetics
COVID-19
Churg-Strauss Syndrome
/ complications
Coronavirus Infections
/ complications
Cyclophosphamide
/ therapeutic use
Drug Therapy, Combination
Glucocorticoids
/ therapeutic use
Granulomatosis with Polyangiitis
/ complications
Humans
Immunocompromised Host
Immunosuppressive Agents
/ therapeutic use
Male
Pandemics
Pneumonia, Viral
/ complications
Prednisolone
/ therapeutic use
RNA, Viral
/ genetics
Reverse Transcriptase Polymerase Chain Reaction
Rituximab
/ therapeutic use
SARS-CoV-2
Treatment Outcome
COVID-19
EGPA
SARS-CoV-2
cyclophosphamide
eosinophilic granulomatosis with polyangiitis
immunosuppression
rituximab
vasculitis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
05
2020
accepted:
31
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Immunosuppressive therapies increase the susceptibility of patients to infections. The current pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compels clinicians to develop recommendations for successful clinical management and surveillance of immunocompromised patients at high risk for severe disease progression. With only few case studies published on SARS-CoV-2 infection in patients with rheumatic diseases, we report a 25-year-old male who developed moderate coronavirus disease 2019 (COVID-19) with fever, mild dyspnea, and no major complications despite having received high-dose prednisolone, cyclophosphamide, and rituximab for the treatment of highly active, life-threatening eosinophilic granulomatosis with polyangiitis (EGPA).
Identifiants
pubmed: 32983161
doi: 10.3389/fimmu.2020.02086
pmc: PMC7484740
doi:
Substances chimiques
Antiviral Agents
0
Glucocorticoids
0
Immunosuppressive Agents
0
RNA, Viral
0
Rituximab
4F4X42SYQ6
Cyclophosphamide
8N3DW7272P
Prednisolone
9PHQ9Y1OLM
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2086Informations de copyright
Copyright © 2020 Schramm, Venhoff, Wagner, Thiel, Huzly, Craig-Mueller, Panning, Hengel, Kern and Voll.
Références
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Arthritis Rheumatol. 2020 Jul 30;:
pubmed: 32734689
J Med Virol. 2020 Apr 28;:
pubmed: 32343415
Nat Rev Immunol. 2020 Jun;20(6):339-341
pubmed: 32317716